For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Kyverna Therapeutics Inc (NASDAQ: KYTX) was $7.94 for the day, down -2.34% from the previous closing price of $8.13. In other words, the price has decreased by -$2.34 from its previous closing price. On the day, 1.28 million shares were traded. KYTX stock price reached its highest trading level at $8.255 during the session, while it also had its lowest trading level at $7.7696.
Ratios:
Our analysis of KYTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.16 and its Current Ratio is at 5.16. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
On May 27, 2025, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $5.
On October 10, 2024, UBS started tracking the stock assigning a Buy rating and target price of $13.UBS initiated its Buy rating on October 10, 2024, with a $13 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 18 ’25 when SEIDENBERG BETH C bought 133,333 shares for $7.50 per share. The transaction valued at 999,998 led to the insider holds 869,317 shares of the business.
Westlake BioPartners Opportuni bought 133,333 shares of KYTX for $999,998 on Dec 18 ’25. The 10% Owner now owns 869,317 shares after completing the transaction at $7.50 per share. On Dec 15 ’25, another insider, Walker Karen Marie, who serves as the Chief Technology Officer of the company, sold 23,998 shares for $12.20 each. As a result, the insider received 292,776 and left with 22,636 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYTX now has a Market Capitalization of 473276448 and an Enterprise Value of 181627584.
Stock Price History:
The Beta on a monthly basis for KYTX is 3.50, which has changed by 1.1394737 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, KYTX has reached a high of $13.67, while it has fallen to a 52-week low of $1.78. The 50-Day Moving Average of the stock is 2.34%, while the 200-Day Moving Average is calculated to be 71.68%.
Shares Statistics:
KYTX traded an average of 1.48M shares per day over the past three months and 1497580 shares per day over the past ten days. A total of 43.79M shares are outstanding, with a floating share count of 28.40M. Insiders hold about 50.28% of the company’s shares, while institutions hold 24.36% stake in the company. Shares short for KYTX as of 1765756800 were 3489945 with a Short Ratio of 2.35, compared to 1763078400 on 3110221. Therefore, it implies a Short% of Shares Outstanding of 3489945 and a Short% of Float of 12.520000000000001.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 5.0 analysts currently analyzing and rating the stock of Kyverna Therapeutics Inc (KYTX).The consensus estimate for the next quarter is -$0.89, with high estimates of -$0.86 and low estimates of -$0.92.
Analysts are recommending an EPS of between -$3.65 and -$4.01 for the fiscal current year, implying an average EPS of -$3.76. EPS for the following year is -$3.59, with 5.0 analysts recommending between -$3.25 and -$3.81.
